- Home
- NEGG vs DCTH Comparison
NEGG vs DCTH Comparison
Compare NEGG & DCTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NEGG
- DCTH
- Stock Information
- Founded
- NEGG 2001
- DCTH 1988
- Country
- NEGG United States
- DCTH United States
- Employees
- NEGG N/A
- DCTH N/A
- Industry
- NEGG Other Specialty Stores
- DCTH Medical/Dental Instruments
- Sector
- NEGG Consumer Discretionary
- DCTH Health Care
- Exchange
- NEGG Nasdaq
- DCTH Nasdaq
- Market Cap
- NEGG 122.3M
- DCTH 485.5M
- IPO Year
- NEGG 2010
- DCTH N/A
- Fundamental
- Price
- NEGG $16.83
- DCTH $12.50
- Analyst Decision
- NEGG
- DCTH Strong Buy
- Analyst Count
- NEGG 0
- DCTH 4
- Target Price
- NEGG N/A
- DCTH $24.00
- AVG Volume (30 Days)
- NEGG 1.3M
- DCTH 785.8K
- Earning Date
- NEGG 08-28-2025
- DCTH 08-04-2025
- Dividend Yield
- NEGG N/A
- DCTH N/A
- EPS Growth
- NEGG N/A
- DCTH N/A
- EPS
- NEGG N/A
- DCTH N/A
- Revenue
- NEGG $1,235,576,000.00
- DCTH $53,850,000.00
- Revenue This Year
- NEGG N/A
- DCTH $155.42
- Revenue Next Year
- NEGG N/A
- DCTH $37.93
- P/E Ratio
- NEGG N/A
- DCTH N/A
- Revenue Growth
- NEGG N/A
- DCTH 1068.87
- 52 Week Low
- NEGG $3.32
- DCTH $7.17
- 52 Week High
- NEGG $26.40
- DCTH $18.23
- Technical
- Relative Strength Index (RSI)
- NEGG 69.10
- DCTH 33.81
- Support Level
- NEGG $15.00
- DCTH $13.30
- Resistance Level
- NEGG $17.74
- DCTH $14.15
- Average True Range (ATR)
- NEGG 2.00
- DCTH 0.64
- MACD
- NEGG 0.44
- DCTH -0.26
- Stochastic Oscillator
- NEGG 90.44
- DCTH 8.28
About NEGG Newegg Commerce Inc.
Newegg Commerce Inc is an e-commerce company offering direct sales and an online marketplace platform for IT computer components, consumer electronics, entertainment, smart home, and gaming products and provides certain third-party logistics services globally. Geographically, it operates in United States, Canada, and Rest of World.
About DCTH Delcath Systems Inc.
Delcath Systems Inc is an oncology company. It is focused on the treatment of primary and metastatic liver cancers. The firm's product, Melphalan Hydrochloride for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.